TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6797752
Drug: Low-dose propranolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propranolol (40 mg every 6 hours)
Study: 6797752
Drug: High-dose propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propranolol (160 mg every 6 hours)
Study: 19491817
Drug: Nootropil (piracetam)
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropil (piracetam) 100 mg/kg daily for 2 months
Study: 15346756
Drug: Standard Brånemark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Brånemark System implants
Study: 15346756
Drug: TiUnite Mk
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiUnite Mk III implants
Study: 9715782
Drug: Lisinopril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10, 20, or 40 mg/day)
Study: 9715782
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (12.5, 25, or 50 mg/day)
Study: 8009196
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg p.o. daily for seven to 12 months
Study: 3066086
Drug: Penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (40 mg/day)
Study: 27364322
Drug: Oral teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral teriflunomide
Study: 27364322
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a
Study: 14609783
Drug: Intravenous phytonadione
Normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phytonadione (0.5 mg for INR 6-10; 1 mg for INR >10)
Study: 14609783
Drug: Oral phytonadione
Normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phytonadione (2.5 mg for INR 6-10; 5 mg for INR >10)
Study: 14609783
Drug: Intravenous phytonadione
Normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phytonadione
Study: 14609783
Drug: Oral phytonadione
Normalized name: Phytonadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phytonadione
Study: 11196267
Drug: ICE chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Study: 1861632
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium fluid (ionized calcium 0 mmol/L)
Study: 1861632
Drug: Control fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control fluid (ionized calcium 1.25 mmol/L)
Study: 1861632
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium fluid (ionized magnesium 0 mmol/L)
Study: 1861632
Drug: No albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No albumin fluid (albumin 0 g/L)
Study: 6226601
Drug: Cimetidine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 1 g orally for 28 days
Study: 31286729
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with hyperbaric oxygen (HBO) therapy, treatment given once every day for 6 courses (5 days on, 2 days off).
Study: 31286729
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy combined with HBO (control group).
Study: 26266376
Drug: Sufentanil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.02 μg/kg/h)
Study: 26266376
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus dexmedetomidine (0.02 μg/kg/h each, Group D1)
Study: 26266376
Drug: Sufentanil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.02 μg/kg/h) plus dexmedetomidine (0.04 μg/kg/h, Group D2)
Study: 24340314
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (PPI-CA) with rabeprazole (20 mg), clarithromycin (500 mg), and amoxicillin (1 g) for 10 days.
Study: 24340314
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (ST) with amoxicillin (1 g) on days 1 to 5, and metronidazole (500 mg) and clarithromycin (500 mg) on days 6 to 10.
Study: 22495940
Drug: COMET +
Normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: COMET + therapy as usual (TAU)
Study: 7690165
Drug: Aprotinin (high-dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high-dosage Trasylol scheme)
Study: 2440683
Drug: aprindine 2
Normalized name: aprindine
DrugBank: Aprindine (DB01429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprindine 2 mg kg‐1
Study: 2440683
Drug: sotalol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol 1.5 mg kg‐1
Study: 2440683
Drug: aprindine 1
Normalized name: aprindine
DrugBank: Aprindine (DB01429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprindine 1 mg kg‐1 & sotalol 0.75 mg kg‐1
Study: 8517099
Drug: Lidocaine 10%
Normalized name: LIDOCAINE 10% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 10% spray
Study: 27412590
Drug: Bromelain (1,050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain (1,050 mg/day)
Study: 27412590
Drug: Placebo (starch-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch-filled capsules)
Study: 25787199
Drug: 30 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 months of dual antiplatelet therapy (continued thienopyridine)
Study: 25787199
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of dual antiplatelet therapy (placebo)
Study: 23279713
Drug: Oral training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral training
Study: 20339966
Drug: Ramipril (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5-5 mg/day)
Study: 10811328
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 20 mg/kg/prednisolone
Study: 10811328
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2 mg/kg/prednisolone
Study: 24930625
Drug: Ramucirumab (10mg/kg)
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab (10mg/kg) + Dacarbazine (1000 mg/m(2)) (Arm A)
Study: 16299436
Drug: Data presented
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data presented as risk difference for treatment outcome
Study: 8527621
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide 0.5 mg
Study: 7547157
Drug: Loperamide oxide
Normalized name: Loperamide oxide
DrugBank: Loperamide oxide (DB14661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide oxide 1 mg
Study: 2275651
Drug: Midazolam to
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam to supplement local anaesthesia
Study: 109935
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa) for 3 months after adrenalectomy-oophorectomy
Study: 109935
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (Control group)
Study: 109935
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa)
Study: 29306475
Drug: Darapladib, 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib, 160mg daily
Study: 22955245
Drug: Cognitive-behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral smoking cessation treatment with 8 weeks of open-label nicotine patch treatment
Study: 18375569
Drug: Oral paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral paliperidone
Study: 18375569
Drug: Oral paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral paliperidone (doses > 3 mg/day)
Study: 16649835
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 32 weeks
Study: 9602961
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg twice daily for 1 week
Study: 2465815
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus combination chemotherapy (cisplatin and vinblastine)
Study: 2465815
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care (palliative radiation, psychosocial support, analgesics, nutritional support)
Study: 1728876
Drug: Oral labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral labetalol
Study: 27786578
Drug: Oral extended
Normalized name: chlorpheniramine maleate 8 MG / codeine phosphate 54.3 MG 12HR Oral Extended Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended release nifedipine
Study: 21726495
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg with 240 ml of 20% glucose solution after a 10 h overnight fasting
Study: 3014770
Drug: Inactivated poliomyelitis
Normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliomyelitis vaccine (IPV)
Study: 3014770
Drug: Oral poliomyelitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliomyelitis vaccine (OPV)
Study: 15364319
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with routine GP IIb/IIIa blockade
Study: 9661556
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with saline for ICB and IM injection of saline (Control group)
Study: 9661556
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with saline for ICB and IM injection of 2 micrograms/kg clonidine (IM group)
Study: 7662226
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg verapamil + 10 mg enalapril
Study: 7662226
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg verapamil + 10 mg enalapril
Study: 1681558
Drug: Loprazolam 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam 1 mg
Study: 2569239
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment (either triazolam or loprazolam)
Study: 772175
Drug: Bromocriptine (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (26 mg daily for 12 weeks)
Study: 26468834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied with GaAlAs, 830 nm wavelength, power of 40 mW, energy of 8.4 J/cm2 dose per spot, applied in 8 treatment sessions at 48-hour intervals
Study: 29368069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser therapy)
Study: 23481125
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (250 mg of standardized soy extract corresponding to isoflavone 100 mg/day)
Study: 20959525
Drug: Aclidinium 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 200 µg
Study: 20959525
Drug: Aclidinium 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 800 µg
Study: 12005077
Drug: Milk basic
Normalized name: Milk Basic Protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk basic protein (MBP) 40 mg per day
Study: 7809577
Drug: Indomethacin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.4 mg/kg body weight as an intravenous bolus followed by continuous infusion of 0.4 mg/kg/h for 6 hours)
Study: 3292590
Drug: Regulated-breathing method
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulated-breathing method (treatment)
Study: 30223773
Drug: Repositioning the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repositioning the R‐DLT into the left main bronchus (Group L)
Study: 30223773
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of lung collapse during one‐lung ventilation (Group L)
Study: 30223773
Drug: Bronchial injuries
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial injuries (Group L)
Study: 30223773
Drug: Vocal cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal cord injuries (Group L)
Study: 20728932
Drug: HEV 239
Normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV 239 vaccine (30 microg of purified recombinant hepatitis E antigen adsorbed to 0.8 mg aluminium hydroxide suspended in 0.5 mL buffered saline)
Study: 23887167
Drug: Placebo (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hepatitis B vaccine)
Study: 18279190
Drug: Hemospan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemospan (200 to 1000 mL)
Study: 15834928
Drug: AC+D (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC+D (neoadjuvant chemotherapy with docetaxel)
Study: 15834928
Drug: AC (neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (neoadjuvant chemotherapy without docetaxel)
Study: 7795834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of weight loss and reduction of dietary sodium
Study: 31277537
Drug: Dihuang Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihuang Decoction (DHD), taken orally, one dose each time, twice a week for one year
Study: 31277537
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium 70 mg orally once a week for one year
Study: 31277537
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of BMD, serum beta-CTX, and serum SOST between DHD and alendronate groups after treatment
Study: 26804967
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2 (dual route/dual release fixed dose combination tablet)
Study: 26804967
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 (testosterone solution for sublingual administration and sildenafil tablet)
Study: 26804967
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2
Study: 26804967
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1
Study: 23477707
Drug: Ticlopidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine plus Ginkgo Biloba extract (250mg ticlopidine plus 80mg Ginkgo Biloba extract twice daily)
Study: 23477707
Drug: Ticlopidine (250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250mg twice daily)
Study: 24942407
Drug: Clopidogrel (75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75mg daily)
Study: 17588604
Drug: Propranolol (one-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (one-day dose)
Study: 10357038
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly ECT
Study: 8348280
Drug: OM-8980 24
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-8980 24 mg
Study: 8348280
Drug: OM-8980 48
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-8980 48 mg
Study: 8348280
Drug: OM-8980 6
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM-8980 6 mg
Study: 3745529
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg twice a day for 5 days
Study: 3745529
Drug: Standard dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosage of oral acyclovir 200 mg five times a day
Study: 19761871
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg b.i.d.)
Study: 24637998
Drug: Standard combined-modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined-modality treatment (including IN-RT)
Study: 21806490
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter with extra‐amniotic saline infusion
Study: 19089532
Drug: Rebamipide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (100 mg TID)
Study: 17200777
Drug: Nadroparin 5750
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 5750 anti‐Xa IU s.c. twice daily
Study: 10676716
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment
Study: 11937423
Drug: Antibiotic monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic monotherapy
Study: 11937423
Drug: Aminoglycoside-containing combination
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside-containing combination therapy
Study: 9701716
Drug: ipsapirone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone (0.3 mg/kg, orally)
Study: 6841923
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (chlorthalidone 15 mg and clonidine 0.1 mg)
Study: 29491276
Drug: Passion fruit
Normalized name: passion fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passion fruit seed extract (5 mg piceatannol)
Study: 24962549
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant human EGF (rhEGF) cream applied twice daily for six weeks
Study: 24962549
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (control) applied twice daily for six weeks
Study: 22424564
Drug: DBS+DOPA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBS+DOPA (both medication and DBS on)
Study: 22424564
Drug: OFF/OFF (off
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFF/OFF (off medication with DBS switched off)
Study: 22424564
Drug: DOPA (on
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOPA (on medication with DBS off)
Study: 17460427
Drug: Early intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early intravitreal triamcinolone injection (4 mg/0.1 ml)
Study: 17460427
Drug: Late intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intravitreal triamcinolone injection (4 mg/0.1 ml)
Study: 15234072
Drug: DAG oil
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG oil (0.5 g/kg body weight/day)
Study: 15234072
Drug: TAG oil
Normalized name: ProVent SKIN TAG OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG oil (0.5 g/kg body weight/day)
Study: 9661552
Drug: i.v. patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. patient-controlled analgesia (PCA) with morphine
Study: 1792811
Drug: Pimobendan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (2.5 mg bid or 5 mg)
Study: 6576203
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose methotrexate (ID-MTX) pulses
Study: 6576203
Drug: COALL-80 induction
Normalized name: coal tar / polysorbate 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: COALL-80 induction therapy modification
Study: 30811354
Drug: Tissue adhesive
Normalized name: Tissue adhesives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue adhesive as an adjunct to standard three-layer closure
Study: 29772277
Drug: 0.1%‐fluorometholone (FML),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1%‐fluorometholone (FML), 4 drops daily for 22 days
Study: 29772277
Drug: Polyvinyl‐alcohol (PA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvinyl‐alcohol (PA), 4 drops daily for 22 days
Study: 26874371
Drug: New lenses
Approvals — FDA: no, EMA: no, PMDA: no
Description: New lenses in new cases with fresh solution (control CLCs)
Study: 18387160
Drug: Colestimide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide (3.0 g/day)
Study: 17704416
Drug: Lapuleucel-T (APC8024)
Normalized name: Lapuleucel-t
DrugBank: Lapuleucel-t (DB19117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapuleucel-T (APC8024) infusion at weeks 0, 2, and 4; no specific dosage mentioned.
Study: 12238277
Drug: Double antibiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double antibiotherapy for 10 to 14 days with a double dose of an anti-secretory drug
Study: 12238277
Drug: Current regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current regimen (7 days of double-dose anti-secretory drug and 2 antibiotics, followed by usual dose for 3 weeks)
Study: 9525444
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg twice daily
Study: 23534896
Drug: Fexofenadine 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 240 mg/day
Study: 9525444
Drug: Fexofenadine 120
Normalized name: fexofenadine hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 120 mg single dose